Company Filing History:
Years Active: 1995-1997
Title: Innovations by Marc Baudrihaye
Introduction
Marc Baudrihaye is a notable inventor based in Waterloo, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative microsphere technologies. With a total of 2 patents, his work focuses on controlled release systems for water-soluble substances.
Latest Patents
Baudrihaye's latest patents include groundbreaking inventions such as "Microspheres for the controlled release of water-soluble substances." This invention features microspheres that are a matrix of a biocompatible and biodegradable polymer, which is soluble in an organic solvent that is immiscible in water. These microspheres are designed to uniformly distribute a water-soluble substance, ensuring that the residual level of toxic solvent remains lower than 1.5% by weight. This technology allows for a progressive and continuous release of the substance over a period of at least 8 days when placed in an aqueous physiological environment, significantly reducing or eliminating the first phase of accelerated release. Another patent focuses on the "Preparation of microparticles for controlled release of water-soluble substances," detailing a process for creating microparticles that control the kinetics of release of the substance.
Career Highlights
Marc Baudrihaye is currently associated with Teva Pharmaceutical Industries Limited, where he applies his expertise in pharmaceutical innovations. His work has been instrumental in advancing drug delivery systems, enhancing the efficacy and safety of medications.
Collaborations
Throughout his career, Baudrihaye has collaborated with esteemed colleagues such as Henri Wantier and Fabienne Mathieu. Their combined efforts have contributed to the successful development of innovative pharmaceutical solutions.
Conclusion
Marc Baudrihaye's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to advancing drug delivery technologies. His work continues to impact the industry positively, paving the way for safer and more effective therapeutic options.